New Drugs In 2013 Show A Virtuous Cycle: First-Cycle Approvals Up, Review Times Down
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Even with half of CDER’s approvals qualifying for longer review timeframes under “the program,” the average time from submission to approval continued its multi-year decline, helped by a record high level of first-cycle approvals. Small molecules and big pharma dominated the 2013 class.
You may also be interested in...
CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014
Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.
FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?
Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
FDA official says the rate of approving applications in the first review cycle may not increase much more, even as the new review model, intended to promote more first-cycle approvals, has yet to finish with its inaugural applications.